Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

Announced by parent company Agios on December X, 2025, the 

 has approved mitapivat under the brand name AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia.

"Despite its severity, treatments [for thalassemia] have historically been limited, leaving some patients without any options," Hanny Al-Samkari, MD, Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Brigham Cancer Institute and associate professor at Harvard Medical School, said in a statement. "The ENERGIZE and ENERGIZE-T Phase 3 trial results demonstrate that AQVESME can help address anemia, fatigue, and the need for regular transfusions - key challenges of the disease."1

Mitapivat is a small-molecule oral activator of pyruvate kinase R (PKR), which is involved in maintaining the energy, health, and longevity of red blood cells. Mitapivat improves red blood cell survival in 

 by increasing ATP and diminishing sickling via decreases in 2,3-diphosphoglycerate.

The FDA’s decision was based on results from the phase 3 ENERGIZE and ENERGIZE-T trials. ENERGIZE was a double-blind, randomized, placebo-controlled trial conducted across 70 hospitals in 18 countries globally. For inclusion, patients had to be ≥18 years with non-transfusion-dependent alpha- and beta-thalassemia and hemoglobin concentrations of ≤10 g/dL.

In ENERGIZE, patients were randomly assigned in a 2:1 ratio to either mitapivat or placebo, both of which were administered at 100 mg orally twice a day for 24 weeks. The primary endpoint was the change in hemoglobin response from baseline.

Ultimately, 194 patients were enrolled, with 130 assigned to mitapivat and 64 to placebo. A total of 7 patients receiving mitapivat and 1 receiving placebo discontinued treatment. 55 patients in the mitapivat group had a hemoglobin response, compared to 1 in the placebo group (least-squares mean difference, 41%; 95% CI, 32-50; 

 <.0001). Adverse events were reported in 107 patients in the mitapivat arm versus 63 in the placebo arm, with the most common being headache, initial insomnia, nausea, and upper respiratory tract infection. No deaths were reported.

The ENERGIZE-T trial was a global, double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of mitapivat versus placebo in adults with transfusion-dependent alpha- or beta-thalassemia. Investigators randomly assigned patients ≥18 years in a 2:1 ratio to mitapivat 100 mg or placebo twice daily for 48 weeks.

ENERGIZE-T's primary endpoint was transfusion reduction response (TRR), defined as a ≥50% reduction in transfused red blood cell (RBC) units and a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period compared with baseline. Key secondary endpoints were TRR2, a ≥50% reduction from baseline in transfused RBC units in any consecutive 24-week period, TRR3, a ≥33% reduction from baseline in transfused RBC units in weeks 13-48, and TRR4, a ≥50% reduction from baseline in transfused RBC units at weeks 13-48.

A total of 258 patients were randomized, with 171 assigned to mitapivat and 87 to placebo. A TRR was achieved in 30.4% of patients in the mitapivat arm versus 12.6% in the placebo arm. Additionally, statistically significant reductions in transfusion burden were demonstrated by all key secondary endpoints: 13.5% versus 2.3% achieved TRR2; 14.6% versus 1.1% achieved TRR3; 7.6% versus 1.1% achieved TRR4.

"Today is a landmark moment for the thalassemia community, bringing forward an innovative, disease-modifying oral medicine to address the urgent needs of people living with this devastating rare blood disorder," Brian Goff, chief executive officer of Agios, said in a statement. "With this approval, AQVESME becomes the only medicine indicated for the treatment of anemia in both non-tranfusion-dependent and transfusion-dependent alpha- or beta-thalassemia."1

Agios Pharmaceuticals. US FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia. December 23, 2025. Accessed December 24, 2025. 

https://investor.agios.com/news-releases/news-release-details/us-fda-approves-agios-aqvesmetm-mitapivat-treatment-anemia

Agios Pharmaceuticals. Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease. November 19, 2025. Accessed December 5, 2025. 

https://investor.agios.com/news-releases/news-release-details/agios-announces-topline-results-rise-phase-3-trial-mitapivat

Taher AT, Al-Samkari H, Aydinok Y, et al. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): A phase 3, International, randomised, double-blind, placebo-controlled trial. The Lancet. 2025;406(10498):33-42. 

Cappellini MD, Sheth S, Taher AT, et al. Energize-T: A global, phase 3, double-blind, randomized, placebo-controlled study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. Blood. 2024;144(Supplement 1):409-409. 

Articles

The FDA has approved mitapivat, branded as AQVESME, for treating anemia in adults with alpha- or beta-thalassemia. This approval is based on the ENERGIZE and ENERGIZE-T Phase 3 trials, which demonstrated significant improvements in hemoglobin levels and reductions in transfusion needs. Mitapivat, an oral activator of pyruvate kinase R, enhances red blood cell survival by increasing ATP levels. The trials showed a notable hemoglobin response and transfusion reduction in patients treated with mitapivat compared to placebo, marking a significant advancement in thalassemia treatment options.

The FDA has approved small-molecule pyruvate kinase R activator mitapivat for the treatment of sickle cell anemia.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hematology

FDA News

FDA Approves Mitapivat (AQVESME) for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia

Stone is professor of medicine at Harvard Medical School and the Edward A Fox Chair in Medicine at the Massachusetts General Hospital. He has treated IgG4-related disease (IgG4-RD) since its emergence in recent years and is passionate about educating patients and fellow healthcare providers (HCPs) about the indolent and systemic nature of this disease.

Current Standards of Care in GCA Treatment

This video covers the following questions:

Let’s shift to discuss current treatments. What is the standard of care for GCA? 

While glucocorticoids have been standard of care for patients with GCA, they are known to elevate the risk of cardiovascular, metabolic, and osteoporotic complications. Please share what you have seen in your clinic.

Videos

Video Series

Current Standards of Care in GCA Treatment 

The Physical and Mental Quality of Life Impacts of GCA

How does GCA impact patient quality of life, particularly in terms of their day-to-day experience? (

What are some of the most significant long-term complications associated with untreated or poorly managed GCA?

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 saw notable regulatory and clinical progress in 2025, with 

 approvals and late-stage trial results expanding treatment options across 

. These developments reinforced nephrology as a rapidly evolving therapeutic field, with growing integration of precision-driven, mechanism-based therapies.

IgAN dominated the headlines, reflecting a shift from supportive care to targeted, disease-modifying strategies. The FDA’s accelerated approval of atrasentan confirmed acceptance of proteinuria-based endpoints, while phase 3 data for telitacicept and sibeprenlimab, alongside interim ORIGIN-3 results for atacicept, highlighted multiple mechanisms, including endothelin A receptor antagonism and BAFF/APRIL inhibition. These advances signal a move toward therapy tailored to disease biology rather than uniform immunosuppression

Complement-targeted therapy matured in rare glomerular disease with FDA approval of pegcetacoplan for C3G and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), marking a durable treatment option and advancing precision nephrology, particularly for post-transplant recurrence. In parallel, transplant innovation progressed as FDA clearance of gene-edited kidney xenotransplant trials moved from concept to early clinical reality, representing a translational step toward addressing organ shortages.

Beyond immune-mediated disease, combination therapy gained traction in CKD with

. The CONFIDENCE trial showed early, simultaneous initiation of finerenone and SGLT2 inhibitors was safe and effective, supporting a proactive approach rather than stepwise escalation.

Taken together, 2025 was pivotal for nephrology, advancing precision-driven, mechanism-based care, supported by regulatory momentum, late-stage trial success, and increasing cardiometabolic integration. Read below for a year in review of

FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease

The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, end-stage kidney disease (ESKD), and cardiovascular death in adults with type 2 diabetes and CKD. The decision was supported by the phase 3b FLOW trial, which demonstrated a 24% relative risk reduction compared with placebo when added to standard therapy.

Semaglutide’s approval reinforces cardio-renal integration, positioning endocrinology and nephrology as co-stewards of CKD progression prevention.

FDA Clears First Xenotransplant Trial for Gene-Edited Kidneys

On February 3, 2025, the FDA cleared United Therapeutics’ IND application to study UKidney™, derived from a 10 gene-edited source pig. The EXPAND trial began in November 2025 at NYU Langone Health with an initial 6-patient cohort, expanding to 50 participants to support a future Biologics License Application. This milestone represents a translational step toward expanding transplant options and may alleviate organ shortages for patients with ESKD.

Atrasentan (Vanrafia) Receives Accelerated Approval in IgA Nephropathy

The FDA granted accelerated approval to atrasentan on April 2, 2025, as the first selective endothelin A receptor antagonist approved to reduce proteinuria in adults with primary IgAN at risk of rapid progression. Approval did not require a REMS, reflecting regulatory confidence in proteinuria as a surrogate endpoint. This decision may broaden targeted therapy use in IgAN and reinforce proteinuria as a valid endpoint for future drug development.

FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis

On June 24, 2025, the FDA approved a 200 mg/mL autoinjector of belimumab for children ≥5 years with active lupus nephritis, complementing the existing approval for pediatric systemic lupus erythematosus. This subcutaneous option allows at-home administration, which may increase adherence and reduce clinic visits, improving real-world disease management for pediatric patients.

FDA Approves Pegcetacoplan (Empaveli) for C3 Glomerulopathy, IC-MPGN

Pegcetacoplan was approved on July 28, 2025, for adolescents and adults with C3G or IC-MPGN, including post-transplant recurrence. Approval followed positive 26-week VALIANT trial results, the largest single trial in these rare diseases. This marks a durable, precision-focused treatment strategy that may shift management of complement-mediated glomerular diseases and improve outcomes in high-risk or post-transplant patients.

VALIANT: Pegcetacoplan Shows Sustained Efficacy in C3G and IC-MPGN, With Carla Nester, MD

CONFIDENCE: SGLT2i and Finerenone Effective, Safe to Initiate Simultaneously in CKD

CONFIDENCE showed simultaneous initiation of finerenone (Kerendia) and empagliflozin (Jardiance) was well-tolerated and produced greater reductions in UACR than either drug alone in CKD with type 2 diabetes. These findings support early, proactive combination therapy, which could redefine standard CKD care by emphasizing simultaneous cardiometabolic intervention.

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study

Telitacicept, a B-cell modulating biologic, achieved a -58.9% change in 24-hour urine protein-to-creatinine ratio versus -8.8% for placebo, with a favorable safety profile. These results highlight the potential of telitacicept to provide a targeted, disease-modifying approach in IgAN, moving treatment away from uniform immunosuppression.

Understanding Atacicept & 36-Week ORIGIN 3 Data from Kidney Week 2025, With Jonathan Barratt, MBChB, PhD

Interim results showed atacicept, a dual BAFF/APRIL inhibitor, reduced Gd-IgA1 by 68.3%, resolved dipstick hematuria in 81% of patients, and reduced UACR by 47.3%. Jonathan Barratt, MBChB, PhD, explained that atacicept may reshape IgAN management by providing a precision approach that addresses underlying pathogenic mechanisms.

BESTOW: Tegoprubart Showcases Safer Prevention of Kidney Transplant Rejection Over Tacrolimus

Phase 2 BESTOW data suggest tegoprubart provides comparable eGFR improvements to tacrolimus but with a superior safety profile, including fewer metabolic and neurologic adverse events. These findings support further evaluation of calcineurin inhibitor–sparing regimens, which could improve long-term graft survival and patient quality of life.

Sibeprenlimab Halves Proteinuria in IgAN in Phase 3 VISIONARY Trial

Interim analysis showed sibeprenlimab reduced proteinuria by 51.2% at 9 months versus placebo. FDA BLA acceptance in May anticipates a potential approval by November 28, 2025. This therapy introduces APRIL-targeted treatment for IgAN, potentially expanding options for patients who may not respond to traditional immunomodulation.

Kidney Compass: Understanding Renal Outcomes in SURPASS-CVOT

Host Brendon Neuen, MBBS, PhD, and Sophia Zoungas, MBBS, PhD, discussed a post hoc analysis of the SURPASS-CVOT trial, showing tirzepatide (Mounjaro) slowed kidney function decline and reduced albuminuria progression compared with dulaglutide (Trulicity) in patients with type 2 diabetes, ASCVD, and high-risk CKD. These findings may guide therapy selection toward agents that confer dual metabolic and renal benefit.

HCPLive Five at European Renal Association (ERA) Congress 2025

Coverage highlighted discussions on pegcetacoplan in C3G and IC-MPGN, 3 IgAN therapies in development, and early combination therapy with finerenone and empagliflozin. These conversations emphasize how emerging therapies and proactive management strategies may influence real-world CKD care and clinical decision-making.

Kidney Compass: The Future of Cardiovascular-Kidney-Metabolic Trial Design

Host Neuen and Shikha Wadhwani, MD, MS, alongside guests Richard Pratley, MD, medical director at the Advent Health Diabetes Institute, and Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, explored strategies to improve trial infrastructure, patient engagement, and evidence generation. This discussion underscores the importance of designing trials that more closely reflect complex, multi-system patient populations in CKD and cardiovascular disease.

Kidney Compass: NUDGE-CKD and the Power of Pragmatic Trials

, Neuen, alongside Tor Biering-Sørensen, MD, MPH, PhD, and Kristoffer Skaarup, MD, discussed the landmark NUDGE-CKD trial, a pragmatic study aimed at improving guideline-based CKD care. This pragmatic approach highlights how evidence generation in real-world settings can inform broader implementation strategies for CKD management.

Kidney Compass: Applying Hierarchical Composite Endpoints in Kidney Disease Trials

, Neuen and Shikha Wadhwani, alongside guests Dustin Little, MD, and Niels Jongs, PhD, examined hierarchical composite endpoints (HCEs) in rare and complex kidney disease trials, emphasizing their potential to optimize trial efficiency, improve data interpretation, and advance therapy development. Adoption of HCEs could accelerate regulatory approval of novel therapies in CKD and rare glomerular diseases.

https://www.hcplive.com/view/fda-approves-semaglutide-ozempic-type-2-diabetes-chronic-kidney-disease

FDA Clears First Xenotransplant Trial for Gene‑Edited Kidneys

https://www.hcplive.com/view/fda-clears-first-xenotransplant-trial-gene-edited-kidneys

https://www.hcplive.com/view/atrasentan-vanrafia-receives-accelerated-approval-in-igan

https://www.hcplive.com/view/fda-approves-belimumab-benlysta-autoinjector-for-pediatric-lupus-nephritis

FDA Approves Pegcetacoplan (Empaveli) for C3 Glomerulopathy, IC‑MPGN

https://www.hcplive.com/view/fda-approves-pegcetacoplan-empaveli-for-c3-glomerulopathy-ic-mpgn

https://www.hcplive.com/view/confidence-sglt2i-and-finerenone-effective-safe-to-initiate-simultaneously-in-ckd

Understanding Atacicept & 36‑Week ORIGIN 3 Data from Kidney Week 2025

https://www.hcplive.com/view/atacicept-36-week-origin-3-data-kidney-week-2025-jonathan-barratt-mbchb-phd

https://www.hcplive.com/view/telitacicept-achieves-primary-endpoint-iga-nephropathy-phase-3-study

https://www.hcplive.com/view/bestow-tegoprubart-showcases-safer-prevention-kidney-transplant-rejection-over-tacrolimus

ERA 2025: Sibeprenlimab Halves Proteinuria in IgAN in Phase 3 VISIONARY Trial

https://www.hcplive.com/view/era-2025-sibeprenlimab-halves-proteinuria-in-igan-in-phase-3-visionary-trial

Kidney Compass: Understanding Renal Outcomes in SURPASS‑CVOT

https://www.hcplive.com/view/kidney-compass-renal-outcomes-in-surpass-cvot-sophia-zoungas

https://www.hcplive.com/view/hcplive-five-at-european-renal-association-era-congress-2025

Kidney Compass: The Future of Cardiovascular‑Kidney‑Metabolic Trial Design

https://www.hcplive.com/view/kidney-compass-the-future-cardiovascular-kidney-metabolic-trial-design

Kidney Compass: NUDGE‑CKD and the Power of Pragmatic Trials

https://www.hcplive.com/view/kidney-compass-nudge-ckd-the-power-pragmatic-trials

https://www.hcplive.com/view/kidney-compass-applying-hierarchical-composite-endpoints-kidney-disease-trials

In 2025, nephrology experienced significant advancements with FDA approvals and trial results enhancing treatment options for chronic kidney disease (CKD), IgA nephropathy (IgAN), lupus nephritis, and C3 glomerulopathy (C3G). These developments emphasized a shift towards precision-driven, mechanism-based therapies. Notable progress included the approval of atrasentan for IgAN, pegcetacoplan for C3G, and semaglutide for CKD in type 2 diabetes. Additionally, gene-edited kidney xenotransplant trials were initiated, and combination therapies gained traction, marking a pivotal year for nephrology with a focus on tailored, proactive care.

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

Nephrology in 2025: Year in Review

Timothy Garvey, MD, is a professor of medicine at the Univeristy of Alabama at Birmingham. 

Oral Semaglutide and the Future of GLP-1 Obesity Treatment, With Timothy Garvey, MD

As highly effective GLP-1-based therapies continue to transform obesity care, their growing use has sharpened attention on safety, patient selection, and the importance of active clinical oversight. While the US Food and Drug Administration (FDA) approval of oral semaglutide (Wegovy) expands access and choice, it also underscores the need for careful risk assessment and long-term management strategies as clinicians incorporate these agents into routine practice.

The December 22, 2025, approval was based on the results from the phase 3 OASIS 4 clinical trial, a 64-week medical study that included 307 adults with obesity or overweight with ≥ 1 weight-related comorbidity, without diabetes. In addition to the oral formulation’s proven efficacy for weight loss, OASIS 4 data showed the most common adverse reactions were similar to those previously seen in clinical trials with semaglutide injection 2.4 mg, including nausea, diarrhea, and vomiting.

In an interview with HCPLive, Timothy Garvey, MD, a professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham, emphasizes that established contraindications remain unchanged across GLP-1 formulations but notes that the therapy is not suitable for patients with contraindications like a history of medullary thyroid carcinoma or acute pancreatitis. He also highlights gallbladder disease as an important clinical consideration, noting that rapid or substantial weight loss, regardless of modality, is associated with increased gallstone risk, with GLP-1 therapies appearing to amplify this effect.

Beyond traditional safety concerns, Garvey calls attention to a more nuanced challenge emerging in real-world practice: excessive weight loss in highly responsive patients. While many individuals benefit substantially from GLP-1–induced weight reduction, some continue losing weight beyond a healthy threshold.

“Some patients just keep losing weight and losing weight, and they can feel tired and run down and listless, and their cognition can even be a little cloudy,” he said. “They don't socialize as well… Some of these patients will say ‘Dr Garvey, I'm losing too much weight. I have to slow down. My friends tell me I don't look good. I look older, I'm tired, I don't have the energy to get things done anymore.’ Other patients will have those same symptoms, but they're kind of enthralled or addicted to the weight loss, and they'll just want to keep losing weight and losing weight. They don't have a perspective on this, and this is where a healthcare professional comes in.”

Adherence considerations also differ between formulations. Oral semaglutide requires daily dosing under specific conditions to optimize absorption, including administration with water on an empty stomach before food intake. Garvey notes that while this regimen may appear burdensome, most patients adapt readily, particularly when oral therapy aligns with their preferences.

Looking ahead, Garvey frames oral semaglutide as part of a rapidly advancing therapeutic continuum. Dual- and triple-agonist agents targeting multiple metabolic pathways are already demonstrating weight loss approaching that of bariatric surgery in clinical trials. However, he cautions that greater potency does not equate to universal need. Increasingly, clinicians are finding success with submaximal dosing, emphasizing individualized treatment rather than maximal weight reduction.

Despite recent progress, Garvey stressed that long-term experience with these second-generation agents remains limited.

“We've only had these medicines since 2021, so we don't have long-term experience. We don't know what the long-term effects will be with bone loss and muscle loss and perhaps 10 years later, more falls and fractures. We just don't know,” Garvey said. “We need a longer term experience, and we need to develop evidence-based strategies for maintaining patients on these medications, promoting adherence, and make sure they take medicines for this chronic disease so they can maintain the health benefits and the weight loss. We're not there yet, so we still have a long way to go.”

Editors’ Note: Garvey reports relevant disclosures with 

Boehringer-Ingelheim, Novo Nordisk, Eli Lilly, Merck, Neurovalens, Fractyl Health, and others.

Brooks A. FDA Approves Semaglutide (Wegovy) Pill As First Oral GLP-1 for Weight Loss. December 22, 2025. Accessed December 24, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-pill-as-first-oral-glp-1-for-weight-loss

Kunzmann K. FDA Approves Semaglutide for Obesity Weight Management. June 4, 2021. Accessed December 24, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-obesity-weight-management

With the FDA approval of oral semaglutide, Garvey weighs safety, oversight, and the future direction of GLP-1 weight management therapy.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Asthma in 2025: Year in Review

Garvey reflects on the recent FDA approval of oral semaglutide (Wegovy) as the first GLP-1 pill for weight loss.

How Oral GLP-1 Therapy Fits Into the Evolving Obesity Treatment Landscape, With Timothy Garvey, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The approval indicates narsoplimab as the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

FDA Approves Narsoplimab (Yartemlea) As First TA-TMA Therapy

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Catch up on some of the biggest alopecia areata news headlines covered by HCPLive from 2025 with this ‘Year in Review’ summary.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Hidradenitis Suppurativa in 2025: Year in Review

The hepatitis year in review covers FDA approvals, HBV and HDV breakthroughs, HCV label expansion, clinical guidelines, and vaccine policy changes.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Hepatitis in 2025: Year in Review

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Therapeutic Updates from the ADA 2026 Standards of Care

The COPD year in review highlights FDA approvals, data, and advances in 2025.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

COPD in 2025: Year in Review

Results of an exclusive Urology Times survey indicate heightened concern among older men about prostate cancer screening.

This Year In Medicine

Prostate Cancer Screening After Biden’s Diagnosis: What Urologists Are Seeing in Practice

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Dyslipidemia in 2025: Year in Review

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Latest News

FDA Approves Mitapivat (AQVESME) for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia

Current Standards of Care in GCA Treatment

The Physical and Mental Quality of Life Impacts of GCA

Nephrology in 2025: Year in Review

Oral Semaglutide and the Future of GLP-1 Obesity Treatment, With Timothy Garvey, MD